These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32550686)

  • 1. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Egeberg A; Girolomoni G; Feldman SR; Radtke MA; Carrascosa JM; Ghil J; Keum JW; Lee J; Seo H
    J Drugs Dermatol; 2020 Mar; 19(3):316-318. PubMed ID: 32550686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.
    Gisondi P; Bianchi L; Calzavara-Pinton P; Conti A; Chiricozzi A; Fimiani M; Pellegrino M; Giunta A; Prignano F; Tiberio R; Venturini M; Girolomoni G
    Br J Dermatol; 2019 Feb; 180(2):409-410. PubMed ID: 30187461
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.
    Lund T; Sand C; Gniadecki R; Thomsen SF
    Dermatol Ther; 2019 May; 32(3):e12846. PubMed ID: 30697879
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center.
    Al Tabaa O; Etcheto A; Dumas S; Batteux F; Goulvestre C; Moltó A; Miceli-Richard C; Dougados M
    Eur J Clin Pharmacol; 2021 Jan; 77(1):25-33. PubMed ID: 32888052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
    Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
    Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
    J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 11. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis.
    Piaserico S; Conti A; Messina F; Meneguzzo A; Odorici G; Bellinato F; Gisondi P
    BioDrugs; 2021 Jul; 35(4):469-471. PubMed ID: 33974243
    [No Abstract]   [Full Text] [Related]  

  • 15. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
    Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
    Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
    Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
    J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.
    Girolomoni G; Feldman SR; Emery P; Ghil J; Keum JW; Cheong SY; Hong E
    Br J Dermatol; 2018 Mar; 178(3):e215-e216. PubMed ID: 29023641
    [No Abstract]   [Full Text] [Related]  

  • 19. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.